Yahoo! Finance: IMMU News

Immunomedics Reports Updated Results of Subcutaneous Humanized Anti-CD20 Antibody Therapy of Lymphoma With Veltuzumab (GlobeNewswire)

Tue, 8 Dec 2009 13:30:00 Etc/GMT

NEW ORLEANS -- Immunomedics, Inc. , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that subcutaneous injections of low doses of veltuzumab in patients with non-Hodgkin's lymphoma achieved sustained serum levels of pharmacologically active antibody, with objective response rates comparable to those seen with higher intravenous doses.

Immunomedics Announces Preclinical Results of Milatuzumab in B-Cell Malignancies (GlobeNewswire)

Mon, 7 Dec 2009 21:30:00 Etc/GMT

Follow-Up Results of Two Clinical Studies With Veltuzumab and Epratuzumab reported At ASH (GlobeNewswire)

Mon, 7 Dec 2009 13:47:06 Etc/GMT

Immunomedics Announces Outcome of 2009 Annual Meeting of Stockholders (GlobeNewswire)

Wed, 2 Dec 2009 18:00:00 Etc/GMT

Immunomedics to Present at 51st ASH Annual Meeting (GlobeNewswire)

Mon, 30 Nov 2009 13:30:00 Etc/GMT

Piper Jaffray Senior Research Analyst Sees M&A Activity As Brisk As Foreign Companies Seek US Specialty Pharmaceutical Distribution Networks (Wall Street Transcript)

Fri, 13 Nov 2009 13:57:00 Etc/GMT

67 WALL STREET, New York - November 13, 2009 - The Wall Street Transcript has just published its Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This 76 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

IMMUNOMEDICS INC Financials (EDGAR Online Financials)

Wed, 11 Nov 2009 14:04:58 Etc/GMT

UBS Research Equity Analyst Picks Top Stocks In Large Cap Biotech Sector (Wall Street Transcript)

Tue, 10 Nov 2009 19:59:00 Etc/GMT

67 WALL STREET, New York - November 10, 2009 - The Wall Street Transcript has recently published its Biotechnology Report offering a timely review of the sector to serious investors and industry executives. This 70 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

New Star Analyst Rankings for Immunomedics, Inc. (StarMine)

Tue, 10 Nov 2009 14:24:52 Etc/GMT

IMMUNOMEDICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (EDGAR Online)

Fri, 6 Nov 2009 13:30:39 Etc/GMT

Immunomedics Announces First Quarter Fiscal 2010 Results and Clinical Program Developments (GlobeNewswire)

Fri, 6 Nov 2009 13:30:00 Etc/GMT

MORRIS PLAINS, N.J. -- Immunomedics, Inc. , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported financial results for the first quarter ended September 30, 2009.

Immunomedics to Present at Upcoming Conferences (GlobeNewswire)

Tue, 27 Oct 2009 12:30:00 Etc/GMT

Immunomedics Receives Corporate Award From New Jersey Inventors Hall of Fame (GlobeNewswire)

Fri, 23 Oct 2009 12:30:00 Etc/GMT

Immunomedics Awarded Three Grants by NIH to Develop New Agents for Imaging and Therapy of Cancer (GlobeNewswire)

Mon, 19 Oct 2009 12:30:00 Etc/GMT

MORRIS PLAINS, N.J. -- Immunomedics, Inc. , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that it has been awarded 3 Small Business Innovation Research grants by the National Institutes of Health , totaling $2.1 million payable over a period of 2 years.

IMMUNOMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (EDGAR Online)

Thu, 15 Oct 2009 15:36:43 Etc/GMT

Further Topline Results for Epratuzumab Phase IIb Study in Systemic Lupus Erythematosus (SLE) (GlobeNewswire)

Thu, 15 Oct 2009 13:31:44 Etc/GMT

MORRIS PLAINS, N.J., Oct. 15, 2009 -- -- Immunomedics , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced further topline results for UCB's new SLE drug candidate epratuzumab.

Mannkind Falls on Talk of Partner, FDA Delay: BioBuzz (at TheStreet.com)

Tue, 6 Oct 2009 14:18:12 Etc/GMT

No Lupus Confab Invite for Immunomedics: BioBuzz (at TheStreet.com)

Tue, 6 Oct 2009 11:42:17 Etc/GMT

Fearful Stocks for Greedy Investors (at Motley Fool)

Mon, 28 Sep 2009 18:44:32 Etc/GMT

3 Stocks Ready to Roar (at Motley Fool)

Wed, 16 Sep 2009 18:18:50 Etc/GMT